These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 36916675)
1. Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis. Southern KW; Castellani C; Lammertyn E; Smyth A; VanDevanter D; van Koningsbruggen-Rietschel S; Barben J; Bevan A; Brokaar E; Collins S; Connett GJ; Daniels TWV; Davies J; Declercq D; Gartner S; Gramegna A; Hamilton N; Hauser J; Kashirskaya N; Kessler L; Lowdon J; Makukh H; Martin C; Morrison L; Nazareth D; Noordhoek J; O'Neill C; Owen E; Oxley H; Raraigh KS; Raynal C; Robinson K; Roehmel J; Schwarz C; Sermet I; Shteinberg M; Sinha I; Takawira C; van Mourik P; Verkleij M; Waller MD; Duff A J Cyst Fibros; 2023 Jan; 22(1):17-30. PubMed ID: 36916675 [TBL] [Abstract][Full Text] [Related]
2. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist. Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995 [TBL] [Abstract][Full Text] [Related]
3. Emerging medicines to improve the basic defect in cystic fibrosis. Fajac I; Sermet-Gaudelus I Expert Opin Emerg Drugs; 2022 Sep; 27(3):229-239. PubMed ID: 35731915 [TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of cystic fibrosis treatment. Carter SC; McKone EF Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265 [TBL] [Abstract][Full Text] [Related]
5. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations. Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449 [TBL] [Abstract][Full Text] [Related]
6. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine. Januska MN; Marx L; Walker PA; Berdella MN; Langfelder-Schwind E J Genet Couns; 2020 Aug; 29(4):607-615. PubMed ID: 32227567 [TBL] [Abstract][Full Text] [Related]
11. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Derichs N Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166 [TBL] [Abstract][Full Text] [Related]
12. An update on new and emerging therapies for cystic fibrosis. Hudock KM; Clancy JP Expert Opin Emerg Drugs; 2017 Dec; 22(4):331-346. PubMed ID: 29264936 [TBL] [Abstract][Full Text] [Related]
13. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Southern KW; Patel S; Sinha IP; Nevitt SJ Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364 [TBL] [Abstract][Full Text] [Related]
14. Standards for the care of people with cystic fibrosis (CF): A timely and accurate diagnosis. Castellani C; Simmonds NJ; Barben J; Addy C; Bevan A; Burgel PR; Drevinek P; Gartner S; Gramegna A; Lammertyn E; Landau EEC; Middleton PG; Plant BJ; Smyth AR; van Koningsbruggen-Rietschel S; Girodon E; Kashirskaya N; Munck A; Nährlich L; Raraigh K; Sermet-Gaudelus I; Sommerburg O; Southern KW J Cyst Fibros; 2023 Nov; 22(6):963-968. PubMed ID: 37775442 [TBL] [Abstract][Full Text] [Related]
15. ECFS standards of care on CFTR-related disorders: Updated diagnostic criteria. Castellani C; De Boeck K; De Wachter E; Sermet-Gaudelus I; Simmonds NJ; Southern KW; J Cyst Fibros; 2022 Nov; 21(6):908-921. PubMed ID: 36220763 [TBL] [Abstract][Full Text] [Related]
16. Towards next generation therapies for cystic fibrosis: Folding, function and pharmacology of CFTR. Bose SJ; Krainer G; Ng DRS; Schenkel M; Shishido H; Yoon JS; Haggie PM; Schlierf M; Sheppard DN; Skach WR J Cyst Fibros; 2020 Mar; 19 Suppl 1(Suppl 1):S25-S32. PubMed ID: 31902693 [TBL] [Abstract][Full Text] [Related]
17. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis. Mayer-Hamblett N; Boyle M; VanDevanter D Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594 [TBL] [Abstract][Full Text] [Related]
18. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis. Cuyx S; De Boeck K Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727 [TBL] [Abstract][Full Text] [Related]
19. Cystic fibrosis - Ten promising therapeutic approaches in the current era of care. Somayaji R; Nichols DP; Bell SC Expert Opin Investig Drugs; 2020 Oct; 29(10):1107-1124. PubMed ID: 32744089 [TBL] [Abstract][Full Text] [Related]
20. Standards for the care of people with cystic fibrosis; establishing and maintaining health. Southern KW; Addy C; Bell SC; Bevan A; Borawska U; Brown C; Burgel PR; Button B; Castellani C; Chansard A; Chilvers MA; Davies G; Davies JC; De Boeck K; Declercq D; Doumit M; Drevinek P; Fajac I; Gartner S; Georgiopoulos AM; Gursli S; Gramegna A; Hansen CM; Hug MJ; Lammertyn E; Landau EEC; Langley R; Mayer-Hamblett N; Middleton A; Middleton PG; Mielus M; Morrison L; Munck A; Plant B; Ploeger M; Bertrand DP; Pressler T; Quon BS; Radtke T; Saynor ZL; Shufer I; Smyth AR; Smith C; van Koningsbruggen-Rietschel S J Cyst Fibros; 2024 Jan; 23(1):12-28. PubMed ID: 38129255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]